ETON Share Price Performance
US$58.86
42.49 (259.56%)
28.9% overvalued intrinsic discount
US$45.67
Fair Value
Price US$58.86
AnalystConsensusTarget US$45.67
AnalystHighTarget US$62.00
AnalystLowTarget US$60.00
Fair ValueUS$45.67
Share Pricen/a
Eton Pharmaceuticals, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 38 Fair Values set on narratives written by author
ETON Community Narratives
AN
Fair Value
·Fair Value US$45.67 28.9% overvalued intrinsic discount
Advances In Diagnosis And Orphan Drugs Will Open New Horizons
0users have liked this narrative
0users have commented on this narrative
12users have followed this narrative
AN
Fair Value
·Fair Value US$62 5.1% undervalued intrinsic discount
Aging Population And Improved Diagnosis Will Unlock Orphan Drug Markets
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
Fair Value
·Fair Value US$60 1.9% undervalued intrinsic discount
Orphan Drug Reliance Will Confront Regulatory Hurdles Yet Regain Traction
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Orphan Drug Reliance Will Confront Regulatory Hurdles Yet Regain Traction
Eton sells a small set of niche medicines for rare conditions, and that focus has helped it grow fast—but it also leaves the business exposed if rules tighten or a rival drug shows up. With more attention on drug pricing and approvals, the big question is whether Eton can keep expanding without losing the pricing power that has fueled its progress so far.Read more
AN
US$60
1.9% undervalued intrinsic discount
Fair Value
Profit Margin
34.13%
Future PE
22.67x
Price in 2029
US$73.5
Aging Population And Improved Diagnosis Will Unlock Orphan Drug Markets
Eton Pharmaceuticals sells treatments for rare diseases, and a mix of better diagnosis and possible label expansions could bring many more patients to its existing medicines sooner than most people expect. The catch is that a small set of products and a reliance on buying or licensing new ones leave the business exposed if competition, pricing pressure, or regulators move against it.Read more
AN
US$62
5.1% undervalued intrinsic discount
Fair Value
Profit Margin
37.61%
Future PE
18.5x
Price in 2029
US$75.68
Advances In Diagnosis And Orphan Drugs Will Open New Horizons
Better testing and awareness mean more people with rare diseases get diagnosed and treated, and Eton Pharmaceuticals aims to benefit by bringing more niche medicines to market. The story hinges on whether its new launches and patient-support programs can keep growth going before pricing pressure and copycat versions of its drugs start to bite.Read more
AN
US$45.67
28.9% overvalued intrinsic discount
Fair Value
Profit Margin
35.63%
Future PE
16.95x
Price in 2029
US$55.74
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
ETON: Ultra Rare Focus And New Guidance Will Drive Future Upside
Fair Value: US$60 1.9% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
ETON: Ultra Rare Disease Focus Will Drive Long Term Upside Potential
Fair Value: US$62 5.1% undervalued intrinsic discount
2 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
ETON: Orphan Therapy Portfolio Expansion Will Reshape Earnings Profile Through 2026
Fair Value: US$45.67 28.9% overvalued intrinsic discount
12 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Eton Pharmaceuticals, Inc. Key Details
About ETON
- Founded
- 2017
- Employees
- 44
- CEO
- WebsiteView website
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
